The financial and time burden associated with phenylketonuria treatment in the United States

ConclusionTreatment for PKU incurs a substantial time and cost burden on persons with PKU and their families. Estimated medical expenditures using claims data varied by age group, but sapropterin represented the largest cost for PKU treatment from a payer perspective across age groups.
Source: Molecular Genetics and Metabolism Reports - Category: Genetics & Stem Cells Source Type: research